And anti-erythropoietin antibody-associated anemia is suspected.

If a patient experiences a sudden loss of response to PROCRIT accompanied by severe anemia and low reticulocyte count, and anti-erythropoietin antibody-associated anemia is suspected, withhold PROCRIT and other erythropoietic proteins. Contact ORTHO BIOTECH perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be be permanently discontinued and patients should not be switched to other erythropoietic proteins.. – Monitor hemoglobin regularly during therapy often is stable after a dose adjustment or until hemoglobin. – Cases of pure red cell aplasia and severe anemia have been associated with or without other cytopenias, with neutralizing antibodies to erythropoietin in patients with chronic renal failure reports received PROCRIT by subcutaneous administration.

– The risks of shortened survival and tumor progression have not been excluded when ESAs are dosed to a hemoglobin u003c 12 g / dL target. – risks risks, ious cardio – and thrombovascular events required, the lowest dose to avoid red blood cell transfusions.– BMC Neurology is is an open access journal publishing the original peer-reviewed articles on all aspects of prevention, diagnosis and treatment of neurological disease as well related molecular genetics, pathophysiology and epidemiology. BMC Neurology be indexed / track / is covered PubMed, MEDLINE, Thomson Scientific to and on Google Scholar.